메뉴 건너뛰기




Volumn 16, Issue 11, 2014, Pages 1087-1095

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

Author keywords

Antihypertensive therapy; Metformin; Pharmacodynamics; Phase I II study; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; CREATININE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; NITROGEN; PLACEBO; UREA; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

EID: 84914154997     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12322     Document Type: Article
Times cited : (206)

References (34)
  • 1
    • 84874291673 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
    • Stenlöf K, Cefalu WT, Kim K-A et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 372-382
    • Stenlöf, K.1    Cefalu, W.T.2    Kim, K.-A.3
  • 2
    • 84891784200 scopus 로고    scopus 로고
    • Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial
    • Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013; 36: 2508-2515.
    • (2013) Diabetes Care , vol.36 , pp. 2508-2515
    • Schernthaner, G.1    Gross, J.L.2    Rosenstock, J.3
  • 3
    • 84876311251 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
    • Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 463-473
    • Yale, J.F.1    Bakris, G.2    Cariou, B.3
  • 4
    • 84880543926 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial
    • Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013; 41: 72-84.
    • (2013) Hosp Pract , vol.41 , pp. 72-84
    • Bode, B.1    Stenlöf, K.2    Sullivan, D.3    Fung, A.4    Usiskin, K.5
  • 5
    • 84884167643 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
    • Cefalu WT, Leiter LA, Yoon K-H et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
    • (2013) Lancet , vol.382 , pp. 941-950
    • Cefalu, W.T.1    Leiter, L.A.2    Yoon, K.-H.3
  • 6
    • 84887997289 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
    • Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-2592.
    • (2013) Diabetologia , vol.56 , pp. 2582-2592
    • Lavalle-González, F.J.1    Januszewicz, A.2    Davidson, J.3
  • 7
    • 84888059660 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
    • Wilding JP, Charpentier G, Hollander P et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282.
    • (2013) Int J Clin Pract , vol.67 , pp. 1267-1282
    • Wilding, J.P.1    Charpentier, G.2    Hollander, P.3
  • 8
    • 84893299467 scopus 로고    scopus 로고
    • Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
    • Stenlof K, Cefalu WT, Kim K-A et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163-175.
    • (2014) Curr Med Res Opin , vol.30 , pp. 163-175
    • Stenlof, K.1    Cefalu, W.T.2    Kim, K.-A.3
  • 9
    • 84893482692 scopus 로고    scopus 로고
    • Canagliflozin (CANA) demonstrates durable glycemic improvements over 104 weeks versus glimepiride (GLIM) in subjects with type 2 diabetes mellitus (T2DM) on metformin (MET) (Abstract 65-LB)
    • Cefalu WT, Leiter LA, Yoon K-H et al. Canagliflozin (CANA) demonstrates durable glycemic improvements over 104 weeks versus glimepiride (GLIM) in subjects with type 2 diabetes mellitus (T2DM) on metformin (MET) (Abstract 65-LB). Diabetes 2013; 62(Suppl. 1): LB18.
    • (2013) Diabetes , vol.62 , pp. LB18
    • Cefalu, W.T.1    Leiter, L.A.2    Yoon, K.-H.3
  • 10
    • 67349189212 scopus 로고    scopus 로고
    • Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
    • Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
    • (2009) Kidney Int , vol.75 , pp. 1272-1277
    • Bakris, G.L.1    Fonseca, V.A.2    Sharma, K.3    Wright, E.M.4
  • 11
    • 67649359913 scopus 로고    scopus 로고
    • From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
    • Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009; 25: 671-681.
    • (2009) Curr Med Res Opin , vol.25 , pp. 671-681
    • Bays, H.1
  • 12
    • 84877710926 scopus 로고    scopus 로고
    • Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus
    • Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: E867-871.
    • (2013) J Clin Endocrinol Metab , vol.98 , pp. E867-E871
    • Polidori, D.1    Sha, S.2    Ghosh, A.3    Plum-Mörschel, L.4    Heise, T.5    Rothenberg, P.6
  • 13
    • 84880320337 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus
    • Devineni D, Curtin CR, Polidori D et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601-610.
    • (2013) J Clin Pharmacol , vol.53 , pp. 601-610
    • Devineni, D.1    Curtin, C.R.2    Polidori, D.3
  • 14
    • 84861781220 scopus 로고    scopus 로고
    • Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
    • Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
    • (2012) Diabetes Care , vol.35 , pp. 1232-1238
    • Rosenstock, J.1    Aggarwal, N.2    Polidori, D.3
  • 15
    • 84914135701 scopus 로고    scopus 로고
    • INVOKANA™ (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals
    • INVOKANA™ (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals, 2013.
    • (2013)
  • 16
    • 84880850027 scopus 로고    scopus 로고
    • Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
    • Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-862.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 853-862
    • Lambers Heerspink, H.J.1    de Zeeuw, D.2    Wie, L.3    Leslie, B.4    List, J.5
  • 17
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
    • (2012) Diabetes Care , vol.35 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 19
    • 36248931664 scopus 로고    scopus 로고
    • The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition
    • Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13: 9-20.
    • (2007) J Manag Care Pharm , vol.13 , pp. 9-20
    • Atlas, S.A.1
  • 20
    • 0027372237 scopus 로고
    • Determination of plasma volume with indocyanine green in man
    • Haller M, Akbulut C, Brechtelsbauer H et al. Determination of plasma volume with indocyanine green in man. Life Sci 1993; 53: 1597-1604.
    • (1993) Life Sci , vol.53 , pp. 1597-1604
    • Haller, M.1    Akbulut, C.2    Brechtelsbauer, H.3
  • 21
    • 33847695696 scopus 로고    scopus 로고
    • Technical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings
    • Jacob M, Conzen P, Finsterer U, Krafft A, Becker BF, Rehm M. Technical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings. J Appl Physiol 2007; 102: 1235-1242.
    • (2007) J Appl Physiol , vol.102 , pp. 1235-1242
    • Jacob, M.1    Conzen, P.2    Finsterer, U.3    Krafft, A.4    Becker, B.F.5    Rehm, M.6
  • 22
    • 0034997098 scopus 로고    scopus 로고
    • Determination of plasma volume by indocyanine green-validation of the method and use in patients after cardiopulmonary bypass
    • Menth-Meier SE, Imoberdorf R, Regli B, Kipfer B, Turgay M, Ballmer PE. Determination of plasma volume by indocyanine green-validation of the method and use in patients after cardiopulmonary bypass. Intensive Care Med 2001; 27: 925-929.
    • (2001) Intensive Care Med , vol.27 , pp. 925-929
    • Menth-Meier, S.E.1    Imoberdorf, R.2    Regli, B.3    Kipfer, B.4    Turgay, M.5    Ballmer, P.E.6
  • 23
    • 47649091315 scopus 로고    scopus 로고
    • Impact of the time window on plasma volume measurement with indocyanine green
    • Jacob M, Chappell D, Conzen P et al. Impact of the time window on plasma volume measurement with indocyanine green. Physiol Meas 2008; 29: 761-770.
    • (2008) Physiol Meas , vol.29 , pp. 761-770
    • Jacob, M.1    Chappell, D.2    Conzen, P.3
  • 24
    • 0024425016 scopus 로고
    • Antipyrine, indocyanine green, and lorazepam determined in plasma by high-pressure liquid chromatography
    • Awni WM, Bakker LJ. Antipyrine, indocyanine green, and lorazepam determined in plasma by high-pressure liquid chromatography. Clin Chem 1989; 35: 2124-2126.
    • (1989) Clin Chem , vol.35 , pp. 2124-2126
    • Awni, W.M.1    Bakker, L.J.2
  • 25
    • 84904517986 scopus 로고    scopus 로고
    • Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method
    • in press
    • Polidori D, Rowley C. Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method. Theor Biol Med Model 2014 (in press).
    • (2014) Theor Biol Med Model
    • Polidori, D.1    Rowley, C.2
  • 26
    • 0033574249 scopus 로고    scopus 로고
    • A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group
    • Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
    • (1999) Ann Intern Med , vol.130 , pp. 461-470
    • Levey, A.S.1    Bosch, J.P.2    Lewis, J.B.3    Greene, T.4    Rogers, N.5    Roth, D.6
  • 27
    • 0343364229 scopus 로고
    • Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension
    • Gifford RWJ, Mattox VR, Orvis AL, Sones DA, Rosevear JW. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension. Circulation 1961; 24: 1197-1205.
    • (1961) Circulation , vol.24 , pp. 1197-1205
    • Gifford, R.W.J.1    Mattox, V.R.2    Orvis, A.L.3    Sones, D.A.4    Rosevear, J.W.5
  • 28
    • 0018891896 scopus 로고
    • Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension
    • van Brummelen P, Schalekamp MA. Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. Acta Med Scand 1980; 207: 259-264.
    • (1980) Acta Med Scand , vol.207 , pp. 259-264
    • van Brummelen, P.1    Schalekamp, M.A.2
  • 30
    • 80052203917 scopus 로고    scopus 로고
    • Quantification of the effect of energy imbalance on bodyweight
    • Hall KD, Sacks G, Chandramohan D et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011; 378: 826-837.
    • (2011) Lancet , vol.378 , pp. 826-837
    • Hall, K.D.1    Sacks, G.2    Chandramohan, D.3
  • 31
    • 0018192282 scopus 로고
    • Mechanism of antihypertensive effect of thiazide diuretics
    • Shah S, Khatri I, Freis ED. Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1978; 95: 611-618.
    • (1978) Am Heart J , vol.95 , pp. 611-618
    • Shah, S.1    Khatri, I.2    Freis, E.D.3
  • 32
    • 0018690043 scopus 로고
    • Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus
    • Weidmann P, Beretta-Piccoli C, Keusch G et al. Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus. Am J Med 1979; 67: 779-784.
    • (1979) Am J Med , vol.67 , pp. 779-784
    • Weidmann, P.1    Beretta-Piccoli, C.2    Keusch, G.3
  • 33
    • 55949096514 scopus 로고    scopus 로고
    • SLC2A9 is a high-capacity urate transporter in humans
    • Caulfield MJ, Munroe PB, O'Neill D et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5: e197.
    • (2008) PLoS Med , vol.5 , pp. e197
    • Caulfield, M.J.1    Munroe, P.B.2    O'Neill, D.3
  • 34
    • 84899852101 scopus 로고    scopus 로고
    • Lower blood pressure (BP) with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) (Abstract 1077-P)
    • Weir MR, Januszewicz A, Gilbert R, Lavalle González F, Meininger G. Lower blood pressure (BP) with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) (Abstract 1077-P). Diabetes 2013; 62(Suppl. 1): A278.
    • (2013) Diabetes , vol.62 , Issue.1 SUPPL , pp. A278
    • Weir, M.R.1    Januszewicz, A.2    Gilbert, R.3    Lavalle González, F.4    Meininger, G.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.